BRPI0814510A2 - Derivados de 6-cicloamino-3-(piridazin-4-il)imidazol[1,2-b]-piridazina, sua preparação e sua aplicação em terapêutica - Google Patents
Derivados de 6-cicloamino-3-(piridazin-4-il)imidazol[1,2-b]-piridazina, sua preparação e sua aplicação em terapêuticaInfo
- Publication number
- BRPI0814510A2 BRPI0814510A2 BRPI0814510-5A2A BRPI0814510A BRPI0814510A2 BR PI0814510 A2 BRPI0814510 A2 BR PI0814510A2 BR PI0814510 A BRPI0814510 A BR PI0814510A BR PI0814510 A2 BRPI0814510 A2 BR PI0814510A2
- Authority
- BR
- Brazil
- Prior art keywords
- cyclamino
- pyridazin
- imidazole
- preparation
- therapeutic application
- Prior art date
Links
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 title 2
- RAXXELZNTBOGNW-UHFFFAOYSA-O Imidazolium Chemical compound C1=C[NH+]=CN1 RAXXELZNTBOGNW-UHFFFAOYSA-O 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Addiction (AREA)
- Psychology (AREA)
- Anesthesiology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US95071107P | 2007-07-19 | 2007-07-19 | |
| FR0705224A FR2918986B1 (fr) | 2007-07-19 | 2007-07-19 | Derives de 6-cycloamino-3-(pyridazin-4-yl)imidazo[1,2-b]- pyridazine, leur preparation et leur application en therapeutique |
| PCT/FR2008/001057 WO2009037394A2 (fr) | 2007-07-19 | 2008-07-18 | DERIVES DE 6-CYCLOAMINO-S-(PYRIDAZIN-YL)IMIDAZO[1,2-b]-PYRIDAZINE, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0814510A2 true BRPI0814510A2 (pt) | 2015-02-03 |
Family
ID=39183122
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0814510-5A2A BRPI0814510A2 (pt) | 2007-07-19 | 2008-07-18 | Derivados de 6-cicloamino-3-(piridazin-4-il)imidazol[1,2-b]-piridazina, sua preparação e sua aplicação em terapêutica |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US8455491B2 (pt) |
| EP (1) | EP2178879B1 (pt) |
| JP (1) | JP5431319B2 (pt) |
| KR (1) | KR20100041771A (pt) |
| CN (1) | CN101784552A (pt) |
| AR (1) | AR069272A1 (pt) |
| AU (1) | AU2008300449A1 (pt) |
| BR (1) | BRPI0814510A2 (pt) |
| CA (1) | CA2693116A1 (pt) |
| CL (1) | CL2008002138A1 (pt) |
| CO (1) | CO6290690A2 (pt) |
| EA (1) | EA016376B1 (pt) |
| ES (1) | ES2429765T3 (pt) |
| FR (1) | FR2918986B1 (pt) |
| MA (1) | MA31616B1 (pt) |
| NZ (1) | NZ582683A (pt) |
| PA (1) | PA8789901A1 (pt) |
| PE (1) | PE20090493A1 (pt) |
| TW (1) | TW200914456A (pt) |
| UY (1) | UY31236A1 (pt) |
| WO (1) | WO2009037394A2 (pt) |
| ZA (1) | ZA201001214B (pt) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7638541B2 (en) | 2006-12-28 | 2009-12-29 | Metabolex Inc. | 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine |
| AU2008279447A1 (en) | 2007-07-19 | 2009-01-29 | Metabolex, Inc. | N-azacyclic substituted pyrrole, pyrazole, imidazole, triazole and tetrazole derivatives as agonists of the RUP3 or GPR119 receptor for the treatment of diabetes and metabolic disorders |
| US7868001B2 (en) * | 2007-11-02 | 2011-01-11 | Hutchison Medipharma Enterprises Limited | Cytokine inhibitors |
| FR2939134A1 (fr) * | 2008-12-01 | 2010-06-04 | Sanofi Aventis | Derives de 6-cycloamino-3-(1h-pyrrolo°2,3-b!pyridin-4-yl) imidazo°1,2-b!-pyridazine, leur preparation et leur application en therapeutique |
| FR2940284B1 (fr) * | 2008-12-19 | 2011-02-18 | Sanofi Aventis | Derives de 6-cycloamino-2,3-di-pyridinyl-imidazo°1,2-b!- pyridazine,leur preparation et leur application en therapeutique |
| FR2940285A1 (fr) | 2008-12-19 | 2010-06-25 | Sanofi Aventis | Derives de 6-cycloamino-2-thienyl-3-(pyridin-4-yl)imidazo °1,2-b!-pyridazine et 6-cycloamino-2-furanyl-3- (pyridin-4-yl)imidazo°1,2-b!-pyridazine, leur preparation et leur application en therapeutique |
| EP2483281B1 (en) | 2009-10-01 | 2014-06-04 | Cymabay Therapeutics, Inc. | Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts |
| EP2491031B1 (en) | 2009-10-23 | 2013-08-07 | Janssen Pharmaceutica N.V. | Fused heterocyclic compounds as orexin receptor modulators |
| ME03452B (me) | 2009-10-23 | 2020-01-20 | Janssen Pharmaceutica Nv | Disupstituisani oktahi-dropirolo[3,4-c]piroli kao modulatori oreksin receptora |
| EP2491034B1 (en) | 2009-10-23 | 2013-12-18 | Janssen Pharmaceutica, N.V. | Fused heterocyclic compounds as orexin receptor modulators |
| PH12012500778A1 (en) | 2009-10-30 | 2012-11-26 | Janssen Pharmaceutica Nv | IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS |
| AR080754A1 (es) | 2010-03-09 | 2012-05-09 | Janssen Pharmaceutica Nv | Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10 |
| BR112012032248A2 (pt) | 2010-06-23 | 2016-09-13 | Metabolex Inc | composições de 5-etil-2-{4-[-4(-4-tetrazol-1-il-fenoximetil)-tiazol-2-il]-piperidin-1-il}-pirimidina |
| CN104803997A (zh) * | 2010-08-09 | 2015-07-29 | 株式会社创药分子设计 | 酪蛋白激酶1δ及酪蛋白激酶1ε抑制剂 |
| EP2651405A2 (en) | 2010-12-14 | 2013-10-23 | Electrophoretics Limited | Casein kinase 1 (ck1 ) inhibitors |
| WO2012145581A1 (en) | 2011-04-20 | 2012-10-26 | Janssen Pharmaceutica Nv | Disubstituted octahy-dropyrrolo [3,4-c] pyrroles as orexin receptor modulators |
| JP6115962B2 (ja) | 2011-06-27 | 2017-04-19 | ヤンセン ファーマシューティカ エヌ.ベー. | 1−アリール−4−メチル−[1,2,4]トリアゾロ[4,3−a]キノキサリン誘導体 |
| WO2014001314A1 (en) | 2012-06-26 | 2014-01-03 | Janssen Pharmaceutica Nv | Combinations comprising pde 2 inhibitors such as 1-aryl-4-methyl- [1,2,4] triazolo [4,3-a] quinoxaline compounds and pde 10 inhibitors for use in the treatment of neurological or metabolic disorders |
| AU2013289284B2 (en) | 2012-07-09 | 2017-03-30 | Janssen Pharmaceutica Nv | Inhibitors of phosphodiesterase 10 enzyme |
| EP2935272B1 (en) | 2012-12-21 | 2017-02-22 | Bristol-Myers Squibb Company | Pyrazole substituted imidazopyrazines as casein kinase 1 d/e inhibitors |
| JP6267231B2 (ja) * | 2012-12-21 | 2018-01-24 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | カゼインキナーゼ1δ/ε阻害剤としての新規な置換イミダゾール |
| GB201321734D0 (en) * | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic Agents |
| ES2728932T3 (es) * | 2014-01-09 | 2019-10-29 | Intra Cellular Therapies Inc | Compuestos orgánicos |
| KR20230116948A (ko) | 2016-03-10 | 2023-08-04 | 얀센 파마슈티카 엔.브이. | 오렉신-2 수용체 길항제를 사용한 우울증의 치료 방법 |
| WO2018026890A1 (en) | 2016-08-03 | 2018-02-08 | Cymabay Therapeutics | Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions |
| AR111295A1 (es) | 2017-03-20 | 2019-06-26 | Forma Therapeutics Inc | Composiciones de pirrolopirrol como activadores de piruvato quinasa (pkr) |
| US10604489B2 (en) | 2018-02-05 | 2020-03-31 | Alkermes, Inc. | Compounds for the treatment of pain |
| WO2020061255A1 (en) | 2018-09-19 | 2020-03-26 | Forma Therapeutics, Inc. | Activating pyruvate kinase r |
| US20200129485A1 (en) | 2018-09-19 | 2020-04-30 | Forma Therapeutics, Inc. | Treating sickle cell disease with a pyruvate kinase r activating compound |
| TW202112368A (zh) | 2019-06-13 | 2021-04-01 | 荷蘭商法西歐知識產權股份有限公司 | 用於治療有關dux4表現之疾病的抑制劑組合 |
| MX2022003025A (es) | 2019-09-19 | 2022-04-07 | Forma Therapeutics Inc | Activacion de la piruvato cinasa r. |
| CN115335057A (zh) * | 2020-03-27 | 2022-11-11 | 北京原基华毅生物科技有限公司 | 抑制酪蛋白激酶的方法 |
| EP4126878A4 (en) * | 2020-03-27 | 2024-07-10 | Gritscience Biopharmaceuticals Co., Ltd. | COMPOUNDS AS CASEIN KINASE INHIBITORS |
| US12128035B2 (en) | 2021-03-19 | 2024-10-29 | Novo Nordisk Health Care Ag | Activating pyruvate kinase R |
| KR20240101561A (ko) | 2021-10-14 | 2024-07-02 | 인사이트 코포레이션 | Kras의 저해제로서의 퀴놀린 화합물 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1989001333A1 (en) * | 1987-08-07 | 1989-02-23 | The Australian National University | IMIDAZO[1,2-b]PYRIDAZINES |
| KR100722176B1 (ko) | 1999-06-08 | 2007-05-29 | 아벤티스 파마슈티칼스 인크. | 일주기 리듬 단백질을 변화시키기 위한 스크리닝 방법 |
| CN100439367C (zh) * | 2003-12-11 | 2008-12-03 | 安万特药物公司 | 作为酪蛋白激酶Iε抑制剂的取代的1H-吡咯并[3,2-b、3,2-c和2,3-c]吡啶-2-甲酰胺以及相关类似物 |
| CA2555263A1 (en) * | 2004-02-12 | 2005-09-01 | Neurogen Corporation | Imidazo-pyridazines, triazolo-pyridazines and related benzodiazepine receptor ligands |
| GB0515026D0 (en) * | 2005-07-21 | 2005-08-31 | Novartis Ag | Organic compounds |
| US20100216798A1 (en) * | 2005-07-29 | 2010-08-26 | Astellas Pharma Inc | Fused heterocycles as lck inhibitors |
| DE102005042742A1 (de) * | 2005-09-02 | 2007-03-08 | Schering Ag | Substituierte Imidazo[1,2b]pyridazine als Kinase-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel |
-
2007
- 2007-07-19 FR FR0705224A patent/FR2918986B1/fr active Active
-
2008
- 2008-07-15 PA PA20088789901A patent/PA8789901A1/es unknown
- 2008-07-17 UY UY31236A patent/UY31236A1/es not_active Application Discontinuation
- 2008-07-17 PE PE2008001220A patent/PE20090493A1/es not_active Application Discontinuation
- 2008-07-17 TW TW097127189A patent/TW200914456A/zh unknown
- 2008-07-18 AU AU2008300449A patent/AU2008300449A1/en not_active Abandoned
- 2008-07-18 AR ARP080103097A patent/AR069272A1/es unknown
- 2008-07-18 EA EA201070161A patent/EA016376B1/ru not_active IP Right Cessation
- 2008-07-18 BR BRPI0814510-5A2A patent/BRPI0814510A2/pt not_active IP Right Cessation
- 2008-07-18 JP JP2010516539A patent/JP5431319B2/ja not_active Expired - Fee Related
- 2008-07-18 CN CN200880103986A patent/CN101784552A/zh active Pending
- 2008-07-18 ES ES08831515T patent/ES2429765T3/es active Active
- 2008-07-18 KR KR1020107001087A patent/KR20100041771A/ko not_active Withdrawn
- 2008-07-18 CL CL2008002138A patent/CL2008002138A1/es unknown
- 2008-07-18 NZ NZ582683A patent/NZ582683A/en not_active IP Right Cessation
- 2008-07-18 CA CA2693116A patent/CA2693116A1/fr not_active Abandoned
- 2008-07-18 WO PCT/FR2008/001057 patent/WO2009037394A2/fr not_active Ceased
- 2008-07-18 EP EP08831515.5A patent/EP2178879B1/fr active Active
-
2010
- 2010-01-11 US US12/685,030 patent/US8455491B2/en not_active Expired - Fee Related
- 2010-01-19 CO CO10004823A patent/CO6290690A2/es not_active Application Discontinuation
- 2010-02-17 MA MA32629A patent/MA31616B1/fr unknown
- 2010-02-19 ZA ZA2010/01214A patent/ZA201001214B/en unknown
-
2013
- 2013-05-06 US US13/887,845 patent/US9108971B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CO6290690A2 (es) | 2011-06-20 |
| AR069272A1 (es) | 2010-01-13 |
| NZ582683A (en) | 2011-07-29 |
| US20100152157A1 (en) | 2010-06-17 |
| EA016376B1 (ru) | 2012-04-30 |
| CA2693116A1 (fr) | 2009-03-26 |
| JP5431319B2 (ja) | 2014-03-05 |
| WO2009037394A2 (fr) | 2009-03-26 |
| AU2008300449A1 (en) | 2009-03-26 |
| UY31236A1 (es) | 2009-03-02 |
| JP2010533686A (ja) | 2010-10-28 |
| CL2008002138A1 (es) | 2009-10-23 |
| US20130245023A1 (en) | 2013-09-19 |
| EP2178879A2 (fr) | 2010-04-28 |
| EA201070161A1 (ru) | 2010-08-30 |
| PA8789901A1 (es) | 2009-02-09 |
| TW200914456A (en) | 2009-04-01 |
| ZA201001214B (en) | 2011-05-25 |
| WO2009037394A3 (fr) | 2009-06-18 |
| MA31616B1 (fr) | 2010-08-02 |
| FR2918986A1 (fr) | 2009-01-23 |
| EP2178879B1 (fr) | 2013-07-03 |
| US9108971B2 (en) | 2015-08-18 |
| PE20090493A1 (es) | 2009-05-27 |
| CN101784552A (zh) | 2010-07-21 |
| KR20100041771A (ko) | 2010-04-22 |
| US8455491B2 (en) | 2013-06-04 |
| ES2429765T3 (es) | 2013-11-15 |
| FR2918986B1 (fr) | 2009-09-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2069342T3 (da) | Derivater af 2-aryl-6-phenyl-imidazol[1,2-A]pyridiner, fremstilling og terapeutisk anvendelse deraf | |
| BRPI0810412A2 (pt) | Derivados de triazolo piridina-carboxamidas e triazolo pirimidina - carboxamidas, o respectivo preparo e a respectiva aplicação em terapêutica | |
| EP1790650A4 (en) | NEW SUBSTITUTED IMIDAZOLE DERIVATIVES | |
| BRPI0908999A2 (pt) | Derivados poli-substituídos de 2-aril-6-imidazo[1,2-a]piridinas, o respectivo preparo e respectiva aplicação em terapêutica | |
| FR2918986B1 (fr) | Derives de 6-cycloamino-3-(pyridazin-4-yl)imidazo[1,2-b]- pyridazine, leur preparation et leur application en therapeutique | |
| BRPI0814807A2 (pt) | Derivados de 6-ciclo amino-3-(piridin-4-il) imidazol[1,2-b}-piridazina, o respectivo preparo e a respectiva aplicação | |
| DK1981889T3 (da) | Cytotoksiske midler, der omfatter nye tomaymycin-derivater, og terapeutisk anvendelse deraf | |
| IL193467A0 (en) | Substituted indazole derivatives, their manufacture and use as pharmaceutical agents | |
| BRPI0817609A2 (pt) | Derivados de imidazol | |
| BRPI0822223A2 (pt) | Derivados de imidazo [1,2-alfa] piridina-2-carboxamidas, sua preparação e sua aplicação em terapêutica | |
| ZA200901268B (en) | Substituted imidazolone derivatives, preparation and uses | |
| BRPI0917939A2 (pt) | derivados de 2-alquil-6-cicloamino-3-(piridin-4-il) imidazo[1,2-b]-piridazina, preparação dos mesmos e aplicação dos mesmos em terapia | |
| ZA200800698B (en) | Pyrazole derivatives as therapeutic agents | |
| BRPI1014269A2 (pt) | derivados de ciclopenta [c] pirrolil-alquilcarbamatos de heterociclos com 5 elementos, preparação dos mesmos e aplicação em terapia. | |
| BRPI0923182A2 (pt) | derivados de 6-cicloamino-2,3-di-piridinil-imidazo[1,2-b]piridazina, o respectivo preparo e a respectivo preparo e a respectiva aplicação terapêutica | |
| IL213581A0 (en) | Derivatives of 6-cycloamino-2-thienyl-3-(pyridin-4-yl)imidazo [1,2-b]-pyridazine and 6-cycloamino-2-furanyl-3-(pyridin-4-yl)imidazo [1,2-b]-pyridazine, preparation and therapeutic application thereof | |
| IL198481A0 (en) | Pyrrole derivatives, preparation use of the same in therapy | |
| BRPI0818863A2 (pt) | Derivados de imidazol | |
| TWI350287B (en) | Acylaminothiazole derivatives, their preparation and their therapeutic application | |
| IL180867A0 (en) | Pyrrole derivatives, their preparation and their therapeutic use | |
| IL193172A0 (en) | Phthalazinone pyrazole derivatives, their manufacture and use as pharmaceutical agents | |
| BRPI0714317A2 (pt) | Utilização de derivados de imidazo [ 1,2-alfa] piridina -21- carboxamidas em terapêutica. | |
| BRPI0821426A2 (pt) | Compostos de n-fenil-imidazol[1,2-a]piridina-2-carboxamidas, o respectivo preparo e a respectiva aplicação em terapêutica. | |
| EP2100588A4 (en) | PROPHYLACTIC OR THERAPEUTIC AGENT AGAINST ALOPEY | |
| DK2234966T3 (da) | Azetidinderivater, fremstilling og terapeutisk anvendelse heraf |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application fees: dismissal - article 86 of industrial property law |
Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES. |
|
| B08K | Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87) |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |